Category: RenalSyndicate content

Renal

Renal Denervation: Medtronic taking another shot at drug-resistant hypertension

February 20, 2015 by Mark Hollmer

Medtronic is taking another shot at renal denervation to treat drug-resistant hypertension, a year after a pivotal trial for its key product in the space failed to meet its efficacy endpoint.

Renal denervation: Analysis highlights 'confounding' factors in Medtronic's Symplicity-3 trial

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Intuitive Surgical study finds its surgical robot pays off over time

February 4, 2015 by Brad Perriello

A massive Intuitive Surgical-backed study finds that using its da Vinci surgical robot to treat kidney cancer is improves outcomes and save costs over the long term.

Intuitive Surgical study finds its surgical robot pays off over time

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

DaVita, Medtronic to study arrhythmia in dialysis patients

November 17, 2014 by Val Kennedy

Cardiac device-maker Medtronic and dialysis-provider DaVita Healthcare Partners plan to team up to identify and study cardiac arrhythmia in patients undergoing dialysis.

DaVita, Medtronic to study arrhythmia in dialysis patients

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

NxStage study highlights advantages of home hemodialysis

November 13, 2014 by Val Kennedy

Home hemodialysis device maker NxStage Medical touts a new study showing that kidney patients who underwent frequent home hemodialysis had a better quality of life and lower risk of death than those who underwent peritoneal dialysis.

NxStage study highlights advantages of home hemodialysis

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

FDA nod triggers $30m milestone for Astute Medical

October 10, 2014 by Alexander Soule

Astute Medical is in line to receive up to $30 million from funding partner CRG to commercialize its recently approved NephroCheck kidney-injury test.

FDA nod triggers $30m milestone for Astute Medical

Astute Medical said it's in line to receive up to $30 million under a standing loan agreement from funding partner CRG to commercialize its recently approved NephroCheck kidney-injury test, and could receive an additional $10 million if it hits certain revenue milestones.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

TCT 2014: Another trial shows no benefit for renal denervation in hypertension

September 17, 2014 by Brad Perriello

Another trial of Medtronic's Symplicity renal denervation device in treating hypertension shows no benefit compared with a sham procedure.

TCT 2014: Another Medtronic trial shows no benefit for renal denervation in hypertension

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Study: CardioMEMs implanted heart monitor safe for renal failure patients

September 16, 2014 by Arezu Sarvestani

New data from CardioMEMs CHAMPION clinical trial shows that the company's implanted pulmonary artery pressure monitor helps reduce heart failure hospitalizations without compromising kidney function in patients with renal failure.

Study: CardioMEMS' implanted sensor safe for renal failure patients

St. Jude Medical (NYSE:STJ) subsidiary CardioMEMs touted new study results this week showing that its implanted heart monitor is safe and effective in patients with chronic kidney disease.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.